CA2300766C - Methode pour traiter une secretion cholinergique influencee - Google Patents

Methode pour traiter une secretion cholinergique influencee Download PDF

Info

Publication number: CA2300766C
Authority: CA; Canada
Prior art keywords: botulinum toxin; units; botulinum; toxin; type
Prior art date: 1993-12-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002300766A

Other languages

English (en)

Other versions

CA2300766A1 (fr

Inventor

K. Roger Aoki

Michael W. Grayston

Steven R. Carlson

Judith M. Leon

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Allergan Inc

Original Assignee

Allergan Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-12-28

Filing date

1994-12-16

Publication date

2008-10-14

1994-12-16 Priority to CA002589989A priority Critical patent/CA2589989C/fr

1994-12-16 Priority to CA002590540A priority patent/CA2590540C/fr

1994-12-16 Priority to CA002590293A priority patent/CA2590293C/fr

1994-12-16 Priority to CA002590537A priority patent/CA2590537C/fr

1994-12-16 Priority to CA002589987A priority patent/CA2589987C/fr

1994-12-16 Application filed by Allergan Inc filed Critical Allergan Inc

1994-12-16 Priority to CA002589968A priority patent/CA2589968A1/fr

1994-12-16 Priority claimed from CA002180011A external-priority patent/CA2180011C/fr

1995-07-06 Publication of CA2300766A1 publication Critical patent/CA2300766A1/fr

2008-10-14 Application granted granted Critical

2008-10-14 Publication of CA2300766C publication Critical patent/CA2300766C/fr

2014-12-16 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108030001720 Bontoxilysin Proteins 0.000 title claims abstract description 50
229940053031 botulinum toxin Drugs 0.000 title claims abstract description 35
206010044074 Torticollis Diseases 0.000 title claims description 15
231100000189 neurotoxic Toxicity 0.000 title claims description 9
230000002887 neurotoxic effect Effects 0.000 title claims description 9
201000002866 cervical dystonia Diseases 0.000 title claims description 5
238000011282 treatment Methods 0.000 claims description 24
108010057266 Type A Botulinum Toxins Proteins 0.000 claims description 10
229940094657 botulinum toxin type a Drugs 0.000 claims description 9
108010069023 botulinum toxin type E Proteins 0.000 claims description 6
108010074523 rimabotulinumtoxinB Proteins 0.000 claims description 6
108700017751 botulinum toxin type C Proteins 0.000 claims description 5
108010069022 botulinum toxin type D Proteins 0.000 claims description 5
108010069038 botulinum toxin type F Proteins 0.000 claims description 5
108010069071 botulinum toxin type G Proteins 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 2
238000007918 intramuscular administration Methods 0.000 claims 2
238000007920 subcutaneous administration Methods 0.000 claims 2
238000000034 method Methods 0.000 abstract description 33
208000007101 Muscle Cramp Diseases 0.000 abstract description 18
208000002193 Pain Diseases 0.000 abstract description 17
208000005392 Spasm Diseases 0.000 abstract description 17
230000036407 pain Effects 0.000 abstract description 17
230000028327 secretion Effects 0.000 abstract description 11
230000001713 cholinergic effect Effects 0.000 abstract description 8
210000003097 mucus Anatomy 0.000 abstract description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
208000035475 disorder Diseases 0.000 abstract description 5
230000035900 sweating Effects 0.000 abstract description 5
206010023644 Lacrimation increased Diseases 0.000 abstract description 4
230000004317 lacrimation Effects 0.000 abstract description 4
239000000203 mixture Substances 0.000 abstract description 4
210000002460 smooth muscle Anatomy 0.000 abstract description 4
208000029578 Muscle disease Diseases 0.000 abstract description 3
208000021642 Muscular disease Diseases 0.000 abstract description 3
210000002565 arteriole Anatomy 0.000 abstract description 3
230000002526 effect on cardiovascular system Effects 0.000 abstract description 3
210000005095 gastrointestinal system Anatomy 0.000 abstract description 3
210000000664 rectum Anatomy 0.000 abstract description 3
210000005070 sphincter Anatomy 0.000 abstract description 3
230000002485 urinary effect Effects 0.000 abstract description 3
210000000232 gallbladder Anatomy 0.000 abstract description 2
230000004118 muscle contraction Effects 0.000 abstract description 2
231100000765 toxin Toxicity 0.000 description 33
239000003053 toxin Substances 0.000 description 33
108700012359 toxins Proteins 0.000 description 33
210000003205 muscle Anatomy 0.000 description 21
239000007924 injection Substances 0.000 description 14
238000002347 injection Methods 0.000 description 14
206010067672 Spasmodic dysphonia Diseases 0.000 description 9
201000002849 spasmodic dystonia Diseases 0.000 description 9
206010043118 Tardive Dyskinesia Diseases 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
230000000694 effects Effects 0.000 description 7
201000006517 essential tremor Diseases 0.000 description 7
208000024891 symptom Diseases 0.000 description 6
241000193155 Clostridium botulinum Species 0.000 description 5
208000025978 Athletic injury Diseases 0.000 description 4
208000008454 Hyperhidrosis Diseases 0.000 description 4
230000002496 gastric effect Effects 0.000 description 4
230000001523 saccharolytic effect Effects 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
208000014094 Dystonic disease Diseases 0.000 description 3
241000792859 Enema Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
208000004350 Strabismus Diseases 0.000 description 3
206010043269 Tension headache Diseases 0.000 description 3
208000008548 Tension-Type Headache Diseases 0.000 description 3
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
229960004373 acetylcholine Drugs 0.000 description 3
231100001103 botulinum neurotoxin Toxicity 0.000 description 3
238000002567 electromyography Methods 0.000 description 3
239000007920 enema Substances 0.000 description 3
229940095399 enema Drugs 0.000 description 3
210000004907 gland Anatomy 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
210000005036 nerve Anatomy 0.000 description 3
208000018360 neuromuscular disease Diseases 0.000 description 3
239000000243 solution Substances 0.000 description 3
206010002091 Anaesthesia Diseases 0.000 description 2
101710117542 Botulinum neurotoxin type A Proteins 0.000 description 2
208000003508 Botulism Diseases 0.000 description 2
241001112696 Clostridia Species 0.000 description 2
241000186581 Clostridium novyi Species 0.000 description 2
208000019505 Deglutition disease Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
102000008100 Human Serum Albumin Human genes 0.000 description 2
108091006905 Human Serum Albumin Proteins 0.000 description 2
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
108010039491 Ricin Proteins 0.000 description 2
108010055044 Tetanus Toxin Proteins 0.000 description 2
238000001949 anaesthesia Methods 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
210000003484 anatomy Anatomy 0.000 description 2
230000001147 anti-toxic effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
206010005159 blepharospasm Diseases 0.000 description 2
230000000744 blepharospasm Effects 0.000 description 2
229940089093 botox Drugs 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
208000006111 contracture Diseases 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
229940098753 dysport Drugs 0.000 description 2
208000010118 dystonia Diseases 0.000 description 2
230000028023 exocytosis Effects 0.000 description 2
229960004716 idoxuridine Drugs 0.000 description 2
239000008176 lyophilized powder Substances 0.000 description 2
210000000715 neuromuscular junction Anatomy 0.000 description 2
239000002581 neurotoxin Substances 0.000 description 2
231100000618 neurotoxin Toxicity 0.000 description 2
201000002851 oromandibular dystonia Diseases 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000003518 presynaptic effect Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000001148 spastic effect Effects 0.000 description 2
241000894007 species Species 0.000 description 2
210000000278 spinal cord Anatomy 0.000 description 2
239000008174 sterile solution Substances 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
229940118376 tetanus toxin Drugs 0.000 description 2
230000001755 vocal effect Effects 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
229940124133 Acetylcholine release inhibitor Drugs 0.000 description 1
208000009017 Athetosis Diseases 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
206010008748 Chorea Diseases 0.000 description 1
241001112695 Clostridiales Species 0.000 description 1
241000186542 Clostridium baratii Species 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
108010059378 Endopeptidases Proteins 0.000 description 1
102000005593 Endopeptidases Human genes 0.000 description 1
240000003550 Eusideroxylon zwageri Species 0.000 description 1
208000003098 Ganglion Cysts Diseases 0.000 description 1
206010061991 Grimacing Diseases 0.000 description 1
208000012659 Joint disease Diseases 0.000 description 1
241000208204 Linum Species 0.000 description 1
208000008930 Low Back Pain Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000008238 Muscle Spasticity Diseases 0.000 description 1
206010062575 Muscle contracture Diseases 0.000 description 1
101710138657 Neurotoxin Proteins 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
206010067171 Regurgitation Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
206010041738 Sports injury Diseases 0.000 description 1
208000005400 Synovial Cyst Diseases 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
208000028911 Temporomandibular Joint disease Diseases 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
208000013142 Writer cramp Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
108010079650 abobotulinumtoxinA Proteins 0.000 description 1
230000009471 action Effects 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
229960001076 chlorpromazine Drugs 0.000 description 1
208000012601 choreatic disease Diseases 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
230000008602 contraction Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
-1 e.g. Proteins 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
229940066758 endopeptidases Drugs 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
210000001097 facial muscle Anatomy 0.000 description 1
201000002865 focal hand dystonia Diseases 0.000 description 1
210000000245 forearm Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
210000003736 gastrointestinal content Anatomy 0.000 description 1
229940095895 haldol Drugs 0.000 description 1
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
208000018197 inherited torticollis Diseases 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
210000002414 leg Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000002232 neuromuscular Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
230000010355 oscillation Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
230000001020 rhythmical effect Effects 0.000 description 1
206010039722 scoliosis Diseases 0.000 description 1
230000036280 sedation Effects 0.000 description 1
239000002689 soil Substances 0.000 description 1
208000018198 spasticity Diseases 0.000 description 1
210000003594 spinal ganglia Anatomy 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
210000002182 synaptic membrane Anatomy 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000036977 tonic contraction Effects 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000563 toxic property Toxicity 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
230000006441 vascular event Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
210000000707 wrist Anatomy 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CA002300766A 1993-12-28 1994-12-16 Methode pour traiter une secretion cholinergique influencee Expired - Lifetime CA2300766C (fr)

Priority Applications (6)

Application Number	Priority Date	Filing Date	Title
CA002590540A CA2590540C (fr)	1993-12-28	1994-12-16	Utilisation du composant neurotoxique d'une toxine botulinique pour le traitement de secretions muqueuses excessives
CA002590293A CA2590293C (fr)	1993-12-28	1994-12-16	Utilisation du composant neurotoxique du botulinum pour le traitement d'un muscle spastique
CA002590537A CA2590537C (fr)	1993-12-28	1994-12-16	Utilisation de la composante neurotoxique de la toxine botulinique pour le traitement du larmoiement excessif
CA002589987A CA2589987C (fr)	1993-12-28	1994-12-16	Methode pour traiter une secretion cholinergique influencee
CA002589989A CA2589989C (fr)	1993-12-28	1994-12-16	Utilisation du composant neurotoxique de la toxine botulinique pour traiter la sudation excessive
CA002589968A CA2589968A1 (fr)	1993-12-28	1994-12-16	Utilisation du composant neurotoxique de la toxine botulinique pour traiter des douleurs associees a l'activite ou la contracture musculaire

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US17399693A	1993-12-28	1993-12-28
US08/173,996		1993-12-28
CA002180011A CA2180011C (fr)	1993-12-28	1994-12-16	Toxines botulinum utilisees dans le traitement de divers troubles, et douleurs associees

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002180011A Division CA2180011C (fr)	1993-12-28	1994-12-16	Toxines botulinum utilisees dans le traitement de divers troubles, et douleurs associees

Related Child Applications (6)

Application Number	Title	Priority Date	Filing Date
CA002589987A Division CA2589987C (fr)	1993-12-28	1994-12-16	Methode pour traiter une secretion cholinergique influencee
CA002590537A Division CA2590537C (fr)	1993-12-28	1994-12-16	Utilisation de la composante neurotoxique de la toxine botulinique pour le traitement du larmoiement excessif
CA002590540A Division CA2590540C (fr)	1993-12-28	1994-12-16	Utilisation du composant neurotoxique d'une toxine botulinique pour le traitement de secretions muqueuses excessives
CA002590293A Division CA2590293C (fr)	1993-12-28	1994-12-16	Utilisation du composant neurotoxique du botulinum pour le traitement d'un muscle spastique
CA002589968A Division CA2589968A1 (fr)	1993-12-28	1994-12-16	Utilisation du composant neurotoxique de la toxine botulinique pour traiter des douleurs associees a l'activite ou la contracture musculaire
CA002589989A Division CA2589989C (fr)	1993-12-28	1994-12-16	Utilisation du composant neurotoxique de la toxine botulinique pour traiter la sudation excessive

Publications (2)

Publication Number	Publication Date
CA2300766A1 CA2300766A1 (fr)	1995-07-06
CA2300766C true CA2300766C (fr)	2008-10-14

Family

ID=25678525

Family Applications (10)

Application Number	Title	Priority Date	Filing Date
CA002300666A Expired - Lifetime CA2300666C (fr)	1993-12-28	1994-12-16	Methode pour traiter la dystonie avec botulinum type b
CA002300433A Abandoned CA2300433A1 (fr)	1993-12-28	1994-12-16	Methode pour traiter les troubles lacrymaux
CA002300386A Expired - Fee Related CA2300386C (fr)	1993-12-28	1994-12-16	Methode pour traiter la dystonie avec des toxines botuliniques de types c, d et e
CA002300703A Expired - Lifetime CA2300703C (fr)	1993-12-28	1994-12-16	Methode pour traiter la sudation excessive
CA002300766A Expired - Lifetime CA2300766C (fr)	1993-12-28	1994-12-16	Methode pour traiter une secretion cholinergique influencee
CA002300663A Expired - Fee Related CA2300663C (fr)	1993-12-28	1994-12-16	Methode pour traiter la dyphagie
CA002300451A Abandoned CA2300451A1 (fr)	1993-12-28	1994-12-16	Methode pour traiter une maladie de la valve pylorique
CA002300464A Expired - Fee Related CA2300464C (fr)	1993-12-28	1994-12-16	Methode pour traiter les maux de tetes
CA002300771A Abandoned CA2300771A1 (fr)	1993-12-28	1994-12-16	Procede pour traiter une secretion muqueuse
CA002300723A Abandoned CA2300723A1 (fr)	1993-12-28	1994-12-16	Methode pour traiter la douleur associe a un muscle

Family Applications Before (4)

Application Number	Title	Priority Date	Filing Date
CA002300666A Expired - Lifetime CA2300666C (fr)	1993-12-28	1994-12-16	Methode pour traiter la dystonie avec botulinum type b
CA002300433A Abandoned CA2300433A1 (fr)	1993-12-28	1994-12-16	Methode pour traiter les troubles lacrymaux
CA002300386A Expired - Fee Related CA2300386C (fr)	1993-12-28	1994-12-16	Methode pour traiter la dystonie avec des toxines botuliniques de types c, d et e
CA002300703A Expired - Lifetime CA2300703C (fr)	1993-12-28	1994-12-16	Methode pour traiter la sudation excessive

Family Applications After (5)

Application Number	Title	Priority Date	Filing Date
CA002300663A Expired - Fee Related CA2300663C (fr)	1993-12-28	1994-12-16	Methode pour traiter la dyphagie
CA002300451A Abandoned CA2300451A1 (fr)	1993-12-28	1994-12-16	Methode pour traiter une maladie de la valve pylorique
CA002300464A Expired - Fee Related CA2300464C (fr)	1993-12-28	1994-12-16	Methode pour traiter les maux de tetes
CA002300771A Abandoned CA2300771A1 (fr)	1993-12-28	1994-12-16	Procede pour traiter une secretion muqueuse
CA002300723A Abandoned CA2300723A1 (fr)	1993-12-28	1994-12-16	Methode pour traiter la douleur associe a un muscle

Country Status (1)

Country	Link
CA (10)	CA2300666C (fr)

1994
- 1994-12-16 CA CA002300666A patent/CA2300666C/fr not_active Expired - Lifetime
- 1994-12-16 CA CA002300433A patent/CA2300433A1/fr not_active Abandoned
- 1994-12-16 CA CA002300386A patent/CA2300386C/fr not_active Expired - Fee Related
- 1994-12-16 CA CA002300703A patent/CA2300703C/fr not_active Expired - Lifetime
- 1994-12-16 CA CA002300766A patent/CA2300766C/fr not_active Expired - Lifetime
- 1994-12-16 CA CA002300663A patent/CA2300663C/fr not_active Expired - Fee Related
- 1994-12-16 CA CA002300451A patent/CA2300451A1/fr not_active Abandoned
- 1994-12-16 CA CA002300464A patent/CA2300464C/fr not_active Expired - Fee Related
- 1994-12-16 CA CA002300771A patent/CA2300771A1/fr not_active Abandoned
- 1994-12-16 CA CA002300723A patent/CA2300723A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
CA2300766A1 (fr)	1995-07-06
CA2300723A1 (fr)	1995-07-06
CA2300703C (fr)	2001-12-11
CA2300666C (fr)	2002-04-30
CA2300663A1 (fr)	1995-07-06
CA2300386C (fr)	2002-04-23
CA2300771A1 (fr)	1995-07-06
CA2300663C (fr)	2003-05-06
CA2300433A1 (fr)	1995-07-06
CA2300464C (fr)	2001-12-11
CA2300451A1 (fr)	1995-07-06
CA2300386A1 (fr)	1995-07-06
CA2300666A1 (fr)	1995-07-06
CA2300464A1 (fr)	1995-07-06
CA2300703A1 (fr)	1995-07-06

Legal Events

Date	Code	Title	Description
2000-03-16	EEER	Examination request
2015-02-17	MKEX	Expiry	Effective date: 20141216

Publication	Publication Date	Title
US6896886B2 (en)	2005-05-24	Use of botulinum toxins for treating various disorders and conditions and associated pain
AU688452B2 (en)	1998-03-12	Botulinum toxins for treating various disorders and associated pain
US20040014663A1 (en)	2004-01-22	Botulinum toxin treatment for cervical dystonia
CA2300766C (fr)	2008-10-14	Methode pour traiter une secretion cholinergique influencee
CA2590293C (fr)	2009-05-12	Utilisation du composant neurotoxique du botulinum pour le traitement d'un muscle spastique